Cargando…

Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (CXMD(J))

BACKGROUND: Matrix metalloproteinases (MMPs) are key regulatory molecules in the formation, remodeling and degradation of all extracellular matrix (ECM) components in both physiological and pathological processes in various tissues. The aim of this study was to examine the involvement of gelatinase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukushima, Kazuhiro, Nakamura, Akinori, Ueda, Hideho, Yuasa, Katsutoshi, Yoshida, Kunihiro, Takeda, Shin'ichi, Ikeda, Shu-ichi
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1929071/ https://www.ncbi.nlm.nih.gov/pubmed/17598883 http://dx.doi.org/10.1186/1471-2474-8-54

Ejemplares similares

Cardiac involvement in Beagle-based canine X-linked muscular dystrophy in Japan (CXMD(J)): electrocardiographic, echocardiographic, and morphologic studies
por: Yugeta, Naoko, et al.
Publicado: (2006)

Dystrophin deficiency in canine X-linked muscular dystrophy in Japan (CXMD(J)) alters myosin heavy chain expression profiles in the diaphragm more markedly than in the tibialis cranialis muscle
por: Yuasa, Katsutoshi, et al.
Publicado: (2008)

Initial Pulmonary Respiration Causes Massive Diaphragm Damage and Hyper-CKemia in Duchenne Muscular Dystrophy Dog
por: Nakamura, Akinori, et al.
Publicado: (2013)

Mammalian Models of Duchenne Muscular Dystrophy: Pathological Characteristics and Therapeutic Applications
por: Nakamura, Akinori, et al.
Publicado: (2011)

Identification of Muscle-Specific MicroRNAs in Serum of Muscular Dystrophy Animal Models: Promising Novel Blood-Based Markers for Muscular Dystrophy
por: Mizuno, Hideya, et al.
Publicado: (2011)

Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors
por: Miyatake, Shouta, et al.
Publicado: (2016)

Exon-Skipping in Duchenne Muscular Dystrophy
por: Takeda, Shin’ichi, et al.
Publicado: (2021)

Progress in muscular dystrophy research with special emphasis on gene therapy
por: SUGITA, Hideo, et al.
Publicado: (2010)

Inflammatory predisposition predicts disease phenotypes in muscular dystrophy
por: Nitahara-Kasahara, Yuko, et al.
Publicado: (2016)

Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy
por: Okada, Takashi, et al.
Publicado: (2013)

Comparison of Experimental Protocols of Physical Exercise for mdx Mice and Duchenne Muscular Dystrophy Patients
por: Hyzewicz, Janek, et al.
Publicado: (2015)

Trends in steroid therapy for Duchenne muscular dystrophy in Japan
por: Takeuchi, Fumi, et al.
Publicado: (2016)

Development of outcome measures according to dystrophic phenotypes in canine X-linked muscular dystrophy in Japan
por: Kuraoka, Mutsuki, et al.
Publicado: (2021)

Characteristics of Japanese Patients with Becker Muscular Dystrophy and Intermediate Muscular Dystrophy in a Japanese National Registry of Muscular Dystrophy (Remudy): Heterogeneity and Clinical Variation
por: Mori-Yoshimura, Madoka, et al.
Publicado: (2018)

Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice
por: Wada, Eiji, et al.
Publicado: (2017)

Early phase 2 trial of TAS‐205 in patients with Duchenne muscular dystrophy
por: Komaki, Hirofumi, et al.
Publicado: (2020)

Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy)
por: Nakamura, Harumasa, et al.
Publicado: (2013)

Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy
por: Taniguchi-Ikeda, Mariko, et al.
Publicado: (2011)

Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches
por: Shimizu-Motohashi, Yuko, et al.
Publicado: (2019)

A phase I study of TAS‐205 in patients with Duchenne muscular dystrophy
por: Takeshita, Eri, et al.
Publicado: (2018)

Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy
por: Ogura, Yuji, et al.
Publicado: (2014)

Rapidly Progressive Heart Failure in a Female Carrier of Becker Muscular Dystrophy with No Skeletal Muscle Symptoms
por: Komoriyama, Hirokazu, et al.
Publicado: (2019)

Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients
por: Takeuchi, Fumi, et al.
Publicado: (2013)

Characterization of a novel microRNA, miR-188, elevated in serum of muscular dystrophy dog model
por: Shibasaki, Hiroyuki, et al.
Publicado: (2019)

Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
por: Tsoumpra, Maria K., et al.
Publicado: (2019)

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
por: Miskew Nichols, Bailey, et al.
Publicado: (2016)

Enhanced cell survival and therapeutic benefits of IL-10-expressing multipotent mesenchymal stromal cells for muscular dystrophy
por: Nitahara-Kasahara, Yuko, et al.
Publicado: (2021)

Efficacy of Prednisolone in Generated Myotubes Derived From Fibroblasts of Duchenne Muscular Dystrophy Patients
por: Kameyama, Tsubasa, et al.
Publicado: (2018)

α1-Syntrophin–deficient skeletal muscle exhibits hypertrophy and aberrant formation of neuromuscular junctions during regeneration
por: Hosaka, Yukio, et al.
Publicado: (2002)

Autophagy in Skeletal Muscle Homeostasis and in Muscular Dystrophies
por: Grumati, Paolo, et al.
Publicado: (2012)

Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy
por: Vila, Maria C, et al.
Publicado: (2017)

Induction of Pluripotent Stem Cells from a Manifesting Carrier of Duchenne Muscular Dystrophy and Characterization of Their X-Inactivation Status
por: Miyagoe-Suzuki, Yuko, et al.
Publicado: (2017)

Clinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network
por: Shimizu, Reiko, et al.
Publicado: (2016)

NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy
por: Watanabe, Naoki, et al.
Publicado: (2018)

Exon 44 skipping in Duchenne muscular dystrophy: NS-089/NCNP-02, a dual-targeting antisense oligonucleotide
por: Watanabe, Naoki, et al.
Publicado: (2023)

Dental pulp stem cells can improve muscle dysfunction in animal models of Duchenne muscular dystrophy
por: Nitahara-Kasahara, Yuko, et al.
Publicado: (2021)

Antioxidants Reduce Muscular Dystrophy in the dy(2J)/dy(2J) Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy
por: Harandi, Vahid M., et al.
Publicado: (2020)

Improved transduction of canine X-linked muscular dystrophy with rAAV9-microdystrophin via multipotent MSC pretreatment
por: Hayashita-Kinoh, Hiromi, et al.
Publicado: (2020)

Bortezomib Does Not Reduce Muscular Dystrophy in the dy(2J)/dy(2J) Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy
por: Körner, Zandra, et al.
Publicado: (2016)

Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy
por: Kao, Kung-Ting, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gtru3jd67hibhvar9pldv5hl5r